1. Scrip
  2. >>Business
  3. >>Strategy

Fate Uncertain As Cell Therapy Biotech Pulls Out Of J&J Deal, Restructures

 
• By Alaric DeArment

The company is discontinuing its lead clinical programs and planning major layoffs as it seeks to reprioritize its pipeline and extend cash runway.

Fate Therapeutics announced the termination of its partnership with J&J and a restructuring • Source: Shutterstock

Fate Therapeutics, Inc. has initiated a major cull of its pipeline, discontinuing its lead clinical programs following the termination of its partnership with Janssen Biotech Inc.. and preparing to lay off more than 200 employees as it seeks to extend cash runway over the next three years. Instead, it will shift its focus to a small handful of much earlier allogeneic cell therapy programs.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

First Quarter M&A Activity Rose On The Strength Of Three Deals

 
• By Joseph Haas

The biopharma sector made acquisitions with total potential value of $33.6bn during Q1, up substantially from the $9.5bn of Q4 2024, according to data from Evaluate.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Trump’s Tariff Rollercoaster Keeps Pharma On Edge

 
• By Jessica Merrill

The rollout of Trump’s tariff plan has been a policy whiplash, but despite a 90-day pause on tariffs, it appears the US president is still holding a grudge with industry over drug pricing.

Trump’s Tariffs Add To European Warning Of $100bn US Exodus

 
• By Andrew McConaghie

European pharma leaders want to see a deal so that no tariffs are imposed on medicines – but they also want the European Union to urgently rethink its sector policies that they believe will lead to massive investment loss.

More from Business

Trump’s Tariff Rollercoaster Keeps Pharma On Edge

 
• By Jessica Merrill

The rollout of Trump’s tariff plan has been a policy whiplash, but despite a 90-day pause on tariffs, it appears the US president is still holding a grudge with industry over drug pricing.

Trump’s Tariffs Add To European Warning Of $100bn US Exodus

 
• By Andrew McConaghie

European pharma leaders want to see a deal so that no tariffs are imposed on medicines – but they also want the European Union to urgently rethink its sector policies that they believe will lead to massive investment loss.

Will Irish Eyes Still Be Smiling When Trump Tariffs Hits Pharma?

 
• By Kevin Grogan

The US president's most recent comments suggest tariffs on pharma are imminent and Ireland has the most to lose.